Yarrow Bioscience Stock (NASDAQ:YARW)


Chart

Previous Close

$30.98

52W Range

$14.05 - $46.95

50D Avg

$36.56

200D Avg

$30.71

Market Cap

$520.52K

Avg Vol (3M)

$27.94K

Beta

2.02

Div Yield

$20.10 (66.40%)

YARW Company Profile


Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Jul 28, 2026

Website

YARW Performance


Latest Earnings Call Transcripts


Q3 21Nov 10, 21 | 8:30 AM
Q2 21Aug 12, 21 | 8:30 AM
Q1 21May 06, 21 | 8:30 AM

Peer Comparison


TickerCompany
XTLBXTL Biopharmaceuticals Ltd.
KALAKALA BIO, Inc.
SNGXSoligenix, Inc.
ENSCEnsysce Biosciences, Inc.
BCLIBrainstorm Cell Therapeutics Inc.
QNRXQuoin Pharmaceuticals, Ltd.
KTTAPasithea Therapeutics Corp.
TCRTAlaunos Therapeutics, Inc.